Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2019

Nov 26, 2019

31949_dirs_2019-11-26_60c831cf-4107-4158-b872-9c3db99ce98a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-11-25

Reporting Person: DOYLE WILLIAM F (Director, Executive Chairman)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-11-25 Ordinary Shares S 16223 $96.04 Disposed 643242 Direct

Footnotes

F1: On November 25, 2019, Mr. Doyle sold 16,223 shares in multiple trades at prices ranging from $96.00 to $96.13. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.